Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Harefuah|October 27, 2017
[PADEH-PORIYA - A CULTURE OF QUALITY AND EXCELLENCE IN THE GALILEE]Avi Peretz, Erez Onn
Journal of Cosmetic Dermatology|November 8, 2022
The burden of gout in acne keloidalis nuchae-Insights from a population-based studyEran Shavit, Arnon Cohen, Lilach Zoller, et al.
Risk Management and Healthcare Policy|December 5, 2014
Time to follow guidelines, protocols, and structured procedures in medical care and time to leap outAyala Kobo-Greenhut, Amos Notea, Meir Ruach, et al.
American Journal of Clinical Dermatology|March 16, 2022
Determinants and Effectiveness of BNT162b2 mRNA Vaccination Among Patients with Atopic Dermatitis: A Population-Based StudyKhalaf Kridin, Yochai Schonmann, Erez Onn, et al.
Archives of Dermatological Research|May 25, 2022
Investigating the epidemiological relationship between vitiligo and psoriasis: a population-based studyKhalaf Kridin, Keren Lyakhovitsky, Erez Onn, et al.
Archives of Dermatological Research|August 29, 2023
A history of asthma is associated with susceptibility to hidradenitis suppurativa: a population-based longitudinal studyKhalaf Kridin, Wesal Shihade, Orly Weinstein, et al.
Health Care Management Review|March 19, 2005
Application of Porter's generic strategies in ambulatory health care: a comparison of managerial perceptions in two Israeli sick fundsRefael Torgovicky, Avishay Goldberg, Shifra Shvarts, et al.
Immunologic Research|October 14, 2021
Risk of COVID-19 and its complications in patients with atopic dermatitis undergoing dupilumab treatment-a population-based cohort studyKhalaf Kridin, Yochai Schonmann, Arie Solomon, et al.
Dermatologic Therapy|May 25, 2021
Tumor necrosis factor inhibitors are associated with a decreased risk of COVID-19-associated hospitalization in patients with psoriasis-A population-based cohort studyKhalaf Kridin, Yochai Schonmann, Giovanni Damiani, et al.
Archives of Dermatological Research|January 15, 2022
Dipeptidyl-peptidase IV inhibitor (DPP4i) confers increased odds of bullous pemphigoid even years after drug initiationKhalaf Kridin, Orly Avni, Giovanni Damiani, et al.
Pageof 3